​

Iovance Biotherapeutics (IOVA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

IOVA Stock Forecast

Iovance Biotherapeutics (IOVA) stock forecast, based on 20 Wall Street analysts, predicts a 12-month average price target of $2.00, with a high of $2.00 and a low of $2.00. This represents a -50.86% decline from the last price of $4.07.

- $4 $8 $12 $16 $20 High: $2 Avg: $2 Low: $2 Last Closed Price: $4.07

IOVA Stock Rating

Iovance Biotherapeutics stock's rating consensus is Buy, based on 20 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (75.00%), 5 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 20 0 5 15 Strong Sell Sell Hold Buy Strong Buy

IOVA Price Target Upside V Benchmarks

TypeNameUpside
StockIovance Biotherapeutics-50.86%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$2.00$2.00
Last Closing Price$4.07$4.07$4.07
Upside/Downside--50.86%-50.86%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26263--11
Feb, 261641-12
Jan, 261641-12
Dec, 251641-12
Nov, 252541-12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 05, 2026Andrea NewkirkGoldman Sachs$2.00$2.44-18.03%-50.86%
May 16, 2025David DaiUBS$2.00$1.6620.48%-50.86%
Feb 28, 2025Piper Sandler$6.00$4.2441.51%47.42%
Jan 31, 2025Joseph CatanzaroPiper Sandler$7.50$5.8528.21%84.28%
Oct 24, 2024David DaiUBS$17.00$9.8273.12%317.69%
Aug 09, 2024Benjamin BurnettStifel Nicolaus$11.50$3.97189.67%182.56%
Aug 09, 2024Colleen KusyRobert W. Baird$12.00$3.97202.27%194.84%
Jul 29, 2024Joseph CatanzaroPiper Sandler$10.00$9.258.11%145.70%
Jun 20, 2024Reni BenjaminJMP Securities$11.50$4.00187.50%182.56%
May 31, 2024Benjamin BurnettStifel Nicolaus$14.00$4.44215.32%243.98%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 05, 2026Goldman SachsSellSellhold
Dec 17, 2025BarclaysOverweightOverweighthold
Nov 24, 2025BarclaysOverweightOverweighthold
Jul 15, 2025Goldman SachsNeutralSelldowngrade
Jul 14, 2025H.C. WainwrightBuyBuyhold
May 16, 2025UBSBuyNeutraldowngrade
Jan 31, 2025Piper SandlerNeutralNeutralhold
Oct 24, 2024UBSBuyinitialise
Aug 14, 2024Cowen & Co.BuyBuyhold
Aug 12, 2024Piper SandlerMarket OutperformMarket Outperformhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.89$-1.28$-1.09---
Avg Forecast$-1.87$-1.26$-0.85$-0.26$0.61$1.21
High Forecast$-1.82$-0.87$-0.47$0.33$1.45$1.26
Low Forecast$-1.89$-1.36$-1.18$-0.82$0.09$1.18
Surprise %1.07%1.59%28.24%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.19M$164.07M$263.50M---
Avg Forecast$4.42M$162.50M$459.05M$762.76M$1.03B$1.32B
High Forecast$10.74M$167.95M$471.71M$770.50M$1.05B$1.36B
Low Forecast$1.79M$160.30M$450.68M$755.03M$1.02B$1.30B
Surprise %-73.11%0.96%-42.60%---

Net Income Forecast

$-450M $-290M $-130M $30M $190M $350M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-444.04M$-372.18M$-390.98M---
Avg Forecast$-444.04M$-262.78M$-249.15M$-68.71M$156.66M$285.10M
High Forecast$-428.17M$-204.92M$-110.50M$77.38M$339.95M$296.90M
Low Forecast$-444.55M$-320.65M$-277.41M$-193.68M$20.92M$278.21M
Surprise %-41.63%56.93%---

IOVA Forecast FAQ

Is Iovance Biotherapeutics stock a buy?

Iovance Biotherapeutics stock has a consensus rating of Buy, based on 20 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Iovance Biotherapeutics is a favorable investment for most analysts.

What is Iovance Biotherapeutics's price target?

Iovance Biotherapeutics's price target, set by 20 Wall Street analysts, averages $2 over the next 12 months. The price target range spans from $2 at the low end to $2 at the high end, suggesting a potential -50.86% change from the previous closing price of $4.07.

How does Iovance Biotherapeutics stock forecast compare to its benchmarks?

Iovance Biotherapeutics's stock forecast shows a -50.86% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Iovance Biotherapeutics over the past three months?

  • March 2026: 18.18% Strong Buy, 54.55% Buy, 27.27% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 8.33% Strong Buy, 50.00% Buy, 33.33% Hold, 8.33% Sell, 0% Strong Sell.
  • January 2026: 8.33% Strong Buy, 50.00% Buy, 33.33% Hold, 8.33% Sell, 0% Strong Sell.

What is Iovance Biotherapeutics’s EPS forecast?

Iovance Biotherapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.26, marking a -76.15% decrease from the reported $-1.09 in 2025. Estimates for the following years are $0.61 in 2027, and $1.21 in 2028.

What is Iovance Biotherapeutics’s revenue forecast?

Iovance Biotherapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $762.76M, reflecting a 189.47% increase from the reported $263.5M in 2025. The forecast for 2027 is $1.03B, and $1.32B for 2028.

What is Iovance Biotherapeutics’s net income forecast?

Iovance Biotherapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-68.714M, representing a -82.43% decrease from the reported $-391M in 2025. Projections indicate $156.66M in 2027, and $285.1M in 2028.